An interventional study of CAREWAY and EM HFLS CWSE(Nine-Motor) in Sputum, sponsored by Pusan National University Yangsan Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This exploratory study aims to evaluate the efficacy and safety of an electromagnetic high-frequency, low-strain chest wall oscillation device for enhancing pulm
64 studies on the registry are indexed under Signs and Symptoms, Respiratory; 9 are open to participants now.
This study's planned enrollment of 45 is below the median of 120 across 43 interventional studies indexed under Signs and Symptoms, Respiratory.
Browse Signs and Symptoms, Respiratory studies →Pusan National University Yangsan Hospital is the lead sponsor of 108 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A high-frequency chest wall oscillation device in the form of a vest (Todaki) is used in patients who require clearance of mucus retained in the lungs, providing high-frequency chest wall vibrations to dislodge sputum adherent to the bronchial walls and facilitate removal of secretions.
Device: CAREWAY
Description:This bed-type medical device delivers vibrational energy across the chest wall for patients with respiratory conditions. aiding in the clearance of accumulated sputum in the airways and lungs. It incorporates nine electromagnetic high-frequency, low-strain vibration motors to produce distributed vibrational energy, which is applied via the chest wall oscillation plate to multiple lung regions, enhancing comprehensive sputum clearance through multi-point oscillation
Device: EM HFLS CWSE(Nine-Motor)
Description: This bed-type medical device applies vibrational energy to the chest wall of patients with respiratory diseases to facilitate sputum clearance from the airways and lungs. The device employs a single electromagnetic high-frequency, low-strain vibration motor that generates vibrational energy, which transmits through the chest wall oscillation plate directly to the patient's chest, promoting effective mucus mobilization via targeted oscillations.
Device: EM HFLS CWSE(Single-motor)
CAREWAY , A high-frequency chest wall oscillation device in the form of a vest (Todaki) is used in patients who require clearance of mucus retained in the lungs, providing high-frequency chest wall vibrations to dislodge sputum adherent to the bronchial walls and facilitate removal of secretions.
This bed-type medical device delivers vibrational energy across the chest wall for patients with respiratory conditions aiding in the clearance of accumulated sputum in the airways and lungs. It incorporates nine electromagnetic high-frequency, low-strain vibration motors to produce distributed vibrational energy, which is applied via the chest wall oscillation plate to multiple lung regions, enhancing comprehensive sputum clearance through multi-point oscillation
This bed-type medical device applies vibrational energy to the chest wall of patients with respiratory diseases , to facilitate sputum clearance from the airways and lungs. The device employs a single electromagnetic high-frequency, low-strain vibration motor that generates vibrational energy, which transmits through the chest wall oscillation plate directly to the patient's chest, promoting effective mucus mobilization via targeted oscillations.
BCSS, Breathlessness, Cough, and Sputum Scale
The Breathlessness, Cough, and Sputum Scale (BCSS) is a patient-reported outcome measure assessing the severity of breathlessness, cough, and sputum. Each symptom is rated by the patient on a numeric scale from 0 (no symptoms) to 4 (severe symptoms). Individual symptom scores and the total score, calculated as the sum of the three items (range 0-12), are used for analysis, with higher scores indicating more severe symptoms.
Time frame: Change rate in Breathlessness, Cough, and Sputum Scale (BCSS) scores at 1 week compared with baseline.
mMRC (modified Medical Research Council Dyspnea Scale)
The modified Medical Research Council (mMRC) Dyspnea Scale is a patient-reported measure assessing the degree of breathlessness during daily activities. Dyspnea severity is rated on a 5-point ordinal scale ranging from 0 (breathlessness only with strenuous exercise) to 4 (too breathless to leave the house or breathless when dressing or undressing). Higher scores indicate more severe dyspnea.
Time frame: Change rate in modified Medical Research Council (mMRC) dyspnea scores at 1 week compared with baseline for patient symptom assessment.
St. George's Respiratory Questionnaire (SGRQ)
The St. George's Respiratory Questionnaire (SGRQ) is a validated patient-reported outcome measure assessing health-related quality of life in patients with respiratory disease. It consists of three domains: Symptoms, Activity, and Impacts. Domain scores and the total score range from 0 to 100, with higher scores indicating worse health status and greater impairment of respiratory-related quality of life.
Time frame: Change rate in St. George's Respiratory Questionnaire (SGRQ) scores at 1 week compared with baseline.
Visual Analog Scale for Dyspnea (VASD)
It is a subjective assessment scale in which patients rate their perceived "difficulty in breathing" from 0 (none) to 10 (worst), and it is used to objectively assess changes in symptoms and evaluate treatment effects in patients with respiratory or cardiac diseases
Time frame: Scores at 1 week compared with baseline.
VAS (Visual Analogue Scale) - Cough
The severity of cough (VAS) is assessed using a Visual Analogue Scale, a subjective method in which patients rate the severity of their cough by marking their symptoms on a straight line from 0 (no cough at all) to 10 (the worst imaginable), which is then recorded as a score.
Time frame: Scores at 1 week compared with baseline.
Cough And Sputum Assessment Questionnaire (CASA-Q)
Cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q), which evaluates symptom severity and impact across four domains. Domain scores range from 0 to 100, with higher scores indicating less severe symptoms and lower disease impact.
Time frame: Scores at 1 week compared with baseline.
Oxygen saturation (SpO2)
Oxygen saturation measured by pulse oximetry, defined as the percentage of hemoglobin saturated with oxygen in arterial blood. Values are expressed as a percentage (%), with higher values indicating better oxygenation status.
Time frame: Data at 1 week compared with baseline.
Forced Vital Capacity (FVC)
Forced vital capacity measured using pulmonary function testing, defined as the maximum volume of air forcibly exhaled after full inspiration. Values are recorded in liters (L).
Time frame: Data at 1 week compared with baseline.
Forced Expiratory Volume in 1 Second (FEV1)
Forced expiratory volume in one second measured using pulmonary function testing, defined as the volume of air forcibly exhaled in the first second of a forced expiration. Values are recorded in liters (L).
Time frame: Data at 1 week compared with baseline.
FEV1/FVC Ratio
The ratio of forced expiratory volume in one second to forced vital capacity measured using pulmonary function testing. Values are expressed as a percentage (%).
Time frame: Data at 1 week compared with baseline.
Forced Expiratory Flow 25-75% (FEF 25-75)
Forced expiratory flow between 25% and 75% of forced vital capacity measured using pulmonary function testing, reflecting airflow in the mid-portion of forced expiration. Values are recorded in liters per second (L/s).
Time frame: Data at 1 week compared with baseline.
Peak Expiratory Flow (PEF)
Peak expiratory flow measured using pulmonary function testing, defined as the maximum flow achieved during a forced expiration. Values are recorded in liters per minute (L/min).
Time frame: Data at 1 week compared with baseline.
Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.
Of 18 interventional studies with no phase under Signs and Symptoms, Respiratory, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 13 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Signs and Symptoms, Respiratory →
Pusan National University Yangsan Hospital →